Back to top

Image: Bigstock

Surmodics, Inc.

Read MoreHide Full Article

Surmodics’ concentrated consumer base, with only a limited number of key customers is concerning at the moment. The company posted stable numbers for the first-quarter fiscal 2017 wherein earnings beat the Zacks Consensus Estimate owing to strong performance in the Medical Device Segment. However performance was muted year over year because of lackluster numbers from the In Vitro Diagnostics segment. Also, the company faces stiff competition in the diagnostics market. However, the company’s shares have outperformed that of the industry in the past one year. Also, the acquisitions of NorMedix and Creagh Medical in the recent past bode well for the company, as it supports management’s growth strategy of expanding the intravascular product solution offerings for medical device customers.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Surmodics, Inc. (SRDX) - free report >>

Published in